Physician profile

Sonum Singh

Endocrinology, Diabetes & Metabolism · Springfield, PA

NPI 1659765873

$15,907.01

in general payments reported to CMS, 2019-2025

36 companies · $12K in 2025

The $12K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$10,098.00
Food and Beverage$3,384.49
Travel and Lodging$840.46
Education$52.49

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Dexcom, INC. $11,359.70 2021-2025 Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter
Novo Nordisk INC $551.08 2022-2025 Ozempic, Rybelsus, Wegovy
Lilly USA, LLC $456.06 2021-2024 Mounjaro, Jardiance, Lyumjev
Medtronic, INC. $357.87 2021-2025 Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g
Amgen INC. $324.94 2021-2025 Tepezza, Repatha
Abbott Laboratories $303.39 2022-2025 Freestyle Libre 3
Bayer Healthcare Pharmaceuticals INC. $292.96 2021-2024
Abbvie INC. $273.62 2021-2025 Synthroid
Xeris Pharmaceuticals, INC. $240.13 2021-2024 Recorlev, Gvoke Hypopen
Sanofi-Aventis U.S. LLC $190.03 2021-2025
Boehringer Ingelheim Pharmaceuticals, INC. $173.68 2021-2025 Jardiance
Tandem Diabetes Care, INC. $173.43 2020-2025 T:Slim X2 Insulin Pump With Control-Iq
Medtronic Minimed, INC. $157.41 2019
Mannkind Corporation $152.61 2021-2025 Afrezza
Becton, Dickinson and Company $108.78 2021-2022
Show all 36 companies
CompanyGeneral paymentsYearsTop products
Ascensia Diabetes Care US INC. $93.52 2022-2024
Amneal Pharmaceuticals LLC $91.26 2021-2022
Alexion Pharmaceuticals, INC. $66.07 2023-2024 Strensiq
Kyowa Kirin, INC. $51.76 2024 Crysvita
Novartis Pharmaceuticals Corporation $49.12 2023-2024
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $45.83 2021-2023 Cycloset
Radius Health, INC. $42.91 2021-2023 Tymlos
Intra-Sana Laboratories $36.83 2025 Glycate, Reltone 200 Mg, Reltone 400 Mg
Ibsa Pharma INC. $36.57 2022-2024 Licart, Tirosint
Horizon Therapeutics Plc $36.27 2022
Amarin Pharma, INC. $28.83 2022-2023
Sequel Med Tech, LLC $26.41 2025 Twiist
Acella Pharmaceuticals, LLC $25.43 2024 NP Thyroid 60
Averitas Pharma INC. $24.81 2024 Qutenza
Merck Sharp & Dohme LLC $23.52 2022
Clarus Therapeutics INC. $23.26 2021
Ipsen Biopharmaceuticals, INC $23.09 2022
Ultragenyx Pharmaceutical INC. $21.38 2021
Opko Pharmaceuticals, LLC $19.46 2024 Rayaldee
Amphastar Pharmaceuticals, INC. $15.76 2023 Baqsimi
Beta Bionics, INC. $9.23 2024 Ilet Bionic Pancreas

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sonum Singh

$15,907.01

in general payments reported 2019-2025

Years
2019-2025
Top company
Dexcom, INC.
Context
The $12K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).

https://glasscript.com/doctor/4836775/sonum-singh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.